Access our dosing table.
Anoro Ellipta 20 mcg
has been lorem added to your basket
Keppra (all doses) is associated with a lower risk of MCM, compared with older AEDs such as valproate and carbamazepine (>700 mg/day) in infants exposed in utero1,2
A longitudinal, prospective cohort study based on the International Registry of Antiepileptic Drugs and Pregnancy (EURAP) from 42 countries. Data collected from 7,555 prospective pregnancies during June 1999 to May 2016. The risk of major congenital malformations was assessed at 1 year after birth in offspring exposed prenatally.1
The same results were first published in Tomson T, et al. Lancet Neurol 2018;17(6):530–538. The graph has been independently created by GSK from the original data.
Comparative risk of MCM in fetuses exposed to different AEDs in utero: data from North American Pregnancy Registry (NAAPR)2
A telephone survey to evaluate the effects of epilepsy and anti-epileptic drugs used during pregnancy on fetal growth and preterm delivery of singleton liveborn infants born to women enrolled in the North American Antiepileptic Drug Pregnancy Registry between 1997 and 2016.2
The same results were first published in Hernandez-Diaz S, et al. Neurology 2012;78(21): 1692–1699. The graph has been independently created by GSK from the original data.
Safety information: Physiological changes during pregnancy may affect levetiracetam concentration. Decrease in levetiracetam plasma concentrations has been observed during pregnancy which is more pronounced in the third trimester.3
*Note that 4000 mg/day is above the approved dose for levetiracetam in epilepsy.
AED: anti-epileptic drug; CBZ: carbamazepine; CNP: clonazepam; EURAP: International Registry of Anti-Epileptic Drugs and Pregnancy; LEV: levetiracetam; LTG: lamotrigine; MCM: major congenital malformations; NAAPR: North American AED Pregnancy Registry; OXC: oxcarbazepine; PB: phenobarbital; PHT: phenytoin; SD: study design; TPM: topiramate; VPA: valproate; WWE: women with epilepsy.
GSK shall not be liable for any damages, claims, liabilities, costs or obligations arising from the use or misuse of information provided herein.
For safety information on GSK products or to report an Adverse Event, please contact the toll free line
0800 CALL GSK (0800 2255 475) or email firstname.lastname@example.org
Full prescribing information is available on request on www.gskpro.com
Please note that it may take up to 10 days to process your request. If you need further assistance contact
GSK House, 1 Industrial Avenue llupeju, Lagos or via email at email@example.com
GlaxoSmithKline Pharmaceutical Nigeria Ltd, 1 Industrial Avenue, llupeju, Lagos 234-1-271 1000
©2020 GSK group of companies or its licensor
Trade marks are owned by or licensed to the GSK group of companies
Keppra is a registered trademark of the GlaxoSmithKline group of companies
PM-NG-LVT-WCNT-200004 Date of preparation: November 2020.